Treats Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy. ANDA 91159, held by MOUNTAIN. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 91159 (Methylphenidate Hydrochloride), held by MOUNTAIN, was first approved by FDA on Mar 12, 2014, with 8 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults Narcolepsy Methylphenidate hydrochloride tablets are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 12, 2014 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Jan 15, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 15, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 15, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jan 15, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 15, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 15, 2026 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 15, 2026 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jan 15, 2026 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 12, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters